Posted by Michael Wonder on 16 Jul 2016
Agenda for the 20 July 2016 TC meeting
15 July 2016 - The Transparency Commission will consider the reimbursement of new medicines and blood products.
The Commission will review capsaicin (Qutenza), eltrombopag olamine (Revolade), dexamethasone (Neofordex), plasma proteins (human) (OctaplasLG), octreotide acetate (Sandostatin), adalimumab (Humira), infliximab (Remicade), etanercept (Enbrel), ustekinumab (Cimzia) and lipiodol (Lipiodal Ultra Fluide).
